Cargando…

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression

Immunosuppression of tumor-infiltrating lymphocytes (TIL) is a common feature of advanced cancer, but its biological basis has remained obscure. We demonstrate here a molecular link between epithelial-to-mesenchymal transition (EMT) and CD8(+) TIL immunosuppression, two key drivers of cancer progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Limo, Gibbons, Don L., Goswami, Sangeeta, Cortez, Maria Angelica, Ahn, Young-Ho, Byers, Lauren A., Zhang, Xuejun, Yi, Xiaohui, Dwyer, David, Lin, Wei, Diao, Lixia, Wang, Jing, Roybal, Jonathon, Patel, Mayuri, Ungewiss, Christin, Peng, David, Antonia, Scott, Mediavilla-Varela, Melanie, Robertson, Gordon, Suraokar, Milind, Welsh, James W., Erez, Baruch, Wistuba, Ignacio I., Chen, Lieping, Peng, Di, Wang, Shanshan, Ullrich, Stephen E., Heymach, John V., Kurie, Jonathan M., Qin, F. Xiao-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212319/
https://www.ncbi.nlm.nih.gov/pubmed/25348003
http://dx.doi.org/10.1038/ncomms6241
Descripción
Sumario:Immunosuppression of tumor-infiltrating lymphocytes (TIL) is a common feature of advanced cancer, but its biological basis has remained obscure. We demonstrate here a molecular link between epithelial-to-mesenchymal transition (EMT) and CD8(+) TIL immunosuppression, two key drivers of cancer progression. We show that microRNA-200 (miR-200), a cell-autonomous suppressor of EMT and metastasis, targets PD-L1. Moreover, ZEB1, an EMT activator and transcriptional repressor of miR-200, relieves miR-200 repression of PD-L1 on tumor cells, leading to CD8(+) T cell immunosuppression and metastasis. These findings are supported by robust correlations between the EMT score, miR-200 levels and PD-L1 expression in multiple human lung cancer datasets. In addition to revealing a link between EMT and T cell dysfunction, these findings also show that ZEB1 promotes metastasis through a heretofore unappreciated cell non-autonomous mechanism, and suggest that subgroups of patients in whom malignant progression is driven by EMT activators may respond to treatment with PD-L1 antagonists.